NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Privi Speciality Q3 FY26 PAT Surges 84% in 9M; Targets ₹5,000 Cr Revenue in 3-4 Years
Privi Speciality Chemicals reported a robust Q3 FY26 with revenue growing 25% YoY to ₹611.15 crores and EBITDA margins sustaining above 25% for the third consecutive quarter. The company is aggressively pursuing its '5k:1k' vision, aiming for ₹5,000 crores in revenue and ₹1,000 crores in EBITDA within 3-4 years. Operational highlights include a capacity expansion from 48,000 MT to 54,000 MT expected by April 2026 and a strategic debt reduction in the Prigiv JV through interest-free advances from Givaudan. Management expects 11-15% volume growth next year, supported by a favorable trade landscape in the US and Europe.
முக்கிய அம்சங்கள்
9M FY26 adjusted PAT grew by 84% YoY to ₹232 crores, driven by operational efficiencies and product mix.EBITDA margins remained strong at 25.83% for Q3, with management guiding for a 20-27% range going forward.Phase 1 capacity expansion to 54,000 MT is on track for commercialization by March/April 2026.Givaudan to provide non-interest-bearing trade advances to the Prigiv JV to significantly reduce debt and interest costs.Company plans a 3-phase expansion to increase overall capacity by 55% over the next 2-3 years.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook given the company's consistent margin profile and clear 2x revenue growth roadmap. The strengthening partnership with Givaudan and upcoming capacity additions provide strong earnings visibility for the next 24 months.
Privi Speciality Q3 FY26 PAT Surges 76% YoY to ₹78 Cr; EBITDA Margins Expand to 25.8%
Privi Speciality Chemicals reported a robust Q3 FY26 with consolidated revenue growing 24% YoY to ₹611.15 crore and PAT jumping 76% to ₹77.99 crore. The company's EBITDA margin expanded by 251 bps to 25.83%, driven by operational efficiencies and a higher share of value-added products. Management reaffirmed its '5k:1k' vision, targeting ₹5,000 crore revenue and ₹1,000 crore EBITDA within 3-4 years, supported by a ₹1,200 crore CAPEX plan. Notably, the PRIGIV joint venture turned EBITDA positive during the quarter.
முக்கிய அம்சங்கள்
9M FY26 Consolidated PAT surged 94% YoY to ₹233.84 crore on revenue of ₹1,857.23 crore.EBITDA margins improved to 25.83% in Q3 FY26, up from 23.32% in the corresponding quarter last year.Planned CAPEX of ₹1,200 crore over 2-3 years to expand capacity and introduce new speciality molecules.PRIGIV JV achieved positive EBITDA; Givaudan to provide ₹150 crore trade advance to reduce JV debt.Net Debt to EBITDA ratio improved significantly to 1.63x (annualized) from 2.25x in FY25.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the turnaround in the PRIGIV joint venture as key growth drivers. The clear roadmap toward doubling revenue and EBITDA over the next 3-4 years makes this a strong candidate for long-term portfolios.
Privi Speciality Q3 Net Profit Up 24.7% to ₹14.87 Cr; ₹25.5 Cr Investment in Givaudan JV
Privi Speciality Chemicals reported a consolidated net profit of ₹14.87 crore for the quarter ended December 31, 2025, marking a 24.7% increase from ₹11.92 crore in the previous year. Total income for the quarter rose to ₹49,305.78 lakhs, up from ₹43,214.14 lakhs year-on-year. The board also approved a ₹50 crore equity infusion into its subsidiary, Prigiv Specialities Private Limited, with Privi contributing ₹25.5 crore to maintain its 51% stake. This investment, alongside JV partner Givaudan SA, is intended to fund growth plans and enhance future profitability.
முக்கிய அம்சங்கள்
Consolidated revenue from operations grew 14.1% YoY to ₹49,305.78 lakhs in Q3 FY26.Net profit for the quarter increased to ₹1,486.64 lakhs compared to ₹1,192.24 lakhs in Q3 FY25.Approved ₹25.5 crore equity investment in subsidiary Prigiv Specialities Private Limited.JV partner Givaudan SA to contribute ₹24.5 crore (49%) to the total ₹50 crore capital infusion.Nine-month consolidated net profit reached ₹4,491.51 lakhs, up from ₹3,548.79 lakhs in the prior year period.
👀 கவனிக்க வேண்டியவை
The company shows consistent double-digit growth in both revenue and profitability while deepening its strategic partnership with global leader Givaudan. Investors should view the continued capital commitment to its subsidiary as a positive sign for long-term capacity and revenue expansion.
Privi Speciality Q3 FY26 Revenue Up 17% to ₹507 Cr; Net Profit Declines 48% YoY
Privi Speciality Chemicals reported a 17.4% YoY growth in consolidated revenue for Q3 FY26, reaching ₹507.38 crore. However, net profit for the quarter saw a significant decline of 48.3% YoY, dropping to ₹12.07 crore from ₹23.34 crore in the previous year. The company also announced a ₹50 crore equity infusion into its subsidiary, Prigiv Specialties, in partnership with Givaudan SA to support future growth. Despite the top-line growth, profitability was impacted by higher operating expenses and finance costs.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations grew 17.4% YoY to ₹507.38 crore in Q3 FY26.Net Profit after tax fell 48.3% YoY to ₹12.07 crore compared to ₹23.34 crore in Q3 FY25.Board approved a ₹50 crore investment in subsidiary Prigiv Specialties, with Privi contributing ₹25.5 crore (51%).Nine-month FY26 net profit stands at ₹44.47 crore, a sharp decline from ₹90.21 crore in 9M FY25.Finance costs for the quarter remained high at ₹21.98 crore, impacting the bottom line.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company is facing significant margin pressure despite healthy revenue growth. Monitor the progress of the Prigiv Specialties expansion and the company's ability to manage rising operational costs in the coming quarters.
Privi Speciality Chemicals Q3 Net Profit Surges 138% to ₹39.06 Cr; ₹50 Cr JV Investment Approved
Privi Speciality Chemicals reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 13.6% YoY to ₹490.87 crore. The company's net profit witnessed a massive surge of 138% YoY, reaching ₹39.06 crore compared to ₹16.38 crore in the corresponding quarter of the previous year. Additionally, the board approved a ₹50 crore equity infusion into its subsidiary, Prigiv Specialties, with Privi contributing ₹25.5 crore (51%) and JV partner Givaudan SA contributing the remainder. This strategic investment is aimed at supporting growth plans and enhancing future profitability.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations increased 13.6% YoY to ₹490.87 crore in Q3 FY26.Net Profit for the quarter surged 138% YoY to ₹39.06 crore from ₹16.38 crore in Q3 FY25.Basic and Diluted EPS improved significantly to ₹10.00 from ₹4.19 in the year-ago period.Approved a ₹50 crore equity investment in Prigiv Specialties Private Limited in a 51:49 ratio with Givaudan SA.Nine-month net profit for the period ended December 31, 2025, stands at ₹120.73 crore, up from ₹86.51 crore YoY.
👀 கவனிக்க வேண்டியவை
The significant expansion in margins and strong bottom-line growth make this a positive result for shareholders. Investors should monitor the progress of the Prigiv Specialties JV investment as it is expected to drive future revenue growth.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Privi Speciality Chemicals Approves Merger of PFSPL and PBPL; Swap Ratio Set at 1:135
The Board of Privi Speciality Chemicals (PSCL) has approved the amalgamation of Privi Fine Sciences (PFSPL) and its wholly-owned subsidiary Privi Biotechnologies (PBPL) into the parent company. For the merger of PFSPL, the company will issue 1 equity share for every 135 shares held by PFSPL shareholders, while PBPL shares will be cancelled as it is a 100% subsidiary. This consolidation aims to integrate 'green science' and biotech R&D capabilities, bringing assets worth approximately ₹324 crore into the main entity. Post-merger, the promoter holding will marginally increase from 69.89% to 70.64%.
முக்கிய அம்சங்கள்
Share exchange ratio of 1 equity share of PSCL for every 135 equity shares of Privi Fine Sciences (PFSPL)Promoter shareholding to increase from 69.89% to 70.64% post-amalgamationConsolidation of assets totaling approximately ₹32,394.77 Lakhs from the two transferor companiesIntegration of a 1,52,444.46 square meter 'green science' land parcel in Jhagadia, GujaratTotal equity share capital to increase from 3,90,62,706 to 4,07,94,775 shares
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic consolidation that simplifies the corporate structure and integrates specialized R&D and green chemistry units. Monitor the timeline for NCLT approvals and the subsequent operational synergies in the aroma chemicals segment.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
